FindTrial
Sign In

Study of the efficacy of the drug memantine in the treatment of fibromialgia

Efficacy of memantine in the treatment of fibromyalgia: an open, uncontrolled, exploratory 3-months follow-up study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-000802-23-ES
Enrollment
Unknown
Registered
2011-11-03
Start date
2011-07-05
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromialgia MedDRA version: 14.0 Level: PT Classification code 10048439 Term: Fibromyalgia System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders

Interventions

Trade Name: EBIXA 5mg+10 mg+15 mg+20 mg comprimidos recubiertos con película Pharmaceutical Form: Film-coated tablet INN or Proposed INN: MEMANTINA HIDROCLORURO Other descriptive name: MEMANTINA HIDRO

Sponsors

Javier García Campayo
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 10 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Timepoint(s) of evaluation of this end point: Basal, 1 month, 3 months;Main Objective: Evaluate the efficacy of memantine in the reduction of glutamate brain levels in patients with fibromialgia;Secondary Objective: Evaluate the efficacy of memantine in the treatnebt of the pain and other symptoms in fibromialgia;Primary end point(s):—

Secondary

MeasureTime frame
Timepoint(s) of evaluation of this end point: Basal, 1 month, 3 months—

Countries

Spain

Contacts

Public ContactJavier García Campayo

Centro Salud El Arrabal

34686673302

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026